ESRRB and neoplasm: Combined treatment with ASOs and trastuzumab in organoids, as well as with vivo-MO and T-DXd in PDX models, significantly inhibited tumor cell growth, highlighting that combined therapy can improve the anti-ERRB2 targeting efficacy, particularly in overcoming ERBB2 resistance (Fig. 5j, k).